EPAMerck, strenghthened by its acquisition of Schering-Plough, becomes the No. 2 drug makerORLANDO, Fla. — A study released Sunday raises fresh concerns about Zetia and its cousin, Vytorin — drugs still taken by millions of Americans to lower cholesterol, despite…

See more here:
Another study questions Merck’s cholesterol medicine, Zetia